|
1
|
Luo M, Li Z, Wang W, Zeng Y, Liu Z and Qiu
J: Long non-coding RNA H19 increases bladder cancer metastasis by
associating with EZH2 and inhibiting E-cadherin expression. Cancer
Lett. 333:213–221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bo J, Yang G, Huo K, Jiang H, Zhang L, Liu
D and Huang Y: microRNA-203 suppresses bladder cancer development
by repressing bcl-w expression. FEBS J. 278:786–292. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stein JP, Grossfeld GD, Ginsberg DA, Esrig
D, Freeman JA, Figueroa AJ, Skinner DG and Cote RJ: Prognostic
markers in bladder cancer: A contemporary review of the literature.
J Urol. 160:645–659. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Laufer M, Ramalingam S, Schoenberg MP,
Haisfieldwolf ME, Zuhowski EG, Trueheart IN, Eisenberger MA, Nativ
O and Egorin MJ: Intravesical gemcitabine therapy for superficial
transitional cell carcinoma of the bladder: A phase I and
pharmacokinetic study. J Clin Oncol. 21:697–703. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shui JW, Steinberg MW and Kronenberg M:
Regulation of inflammation, autoimmunity and infection immunity by
HVEM-BTLA signaling. J Leukoc Biol. 89:517–523. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bolyard C, Ji YY, Wang PY, Saini U, Rath
KS, Cripe T, Zhang J, Selvendiran K and Kaur B: Doxorubicin
synergizes with 34.5 ENVE to enhance antitumor efficacy against
metastatic ovarian cancer. Clin Cancer Res. 20:6479–6494. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shui JW, Larange A, Kim G, Vela JL, Zahner
S, Cheroutre H and Kronenberg M: HVEM signalling at mucosal
barriers provides host defence against pathogenic bacteria. Nature.
488:222–225. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Salipante SJ, Adey A, Thomas A, Lee C, Liu
YJ, Kumar A, Lewis AP, Wu D, Fromm JR and Shendure J: Recurrent
somatic loss of TNFRSF14 in classical Hodgkin lymphoma. Genes
Chromosomes Cancer. 55:278–287. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kotsiou E, Okosun J, Besley C, Iqbal S,
Matthews J, Fitzgibbon J, Gribben JG and Davies JK: TNFRSF14
aberrations in follicular lymphoma increase clinically significant
allogeneic T-cell responses. Blood. 128:72–81. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cheung KJ, Johnson NA, Affleck JG,
Severson T, Steidl C, Ben-Neriah S, Schein J, Morin RD, Moore R,
Shah SP, et al: Acquired TNFRSF14 mutations in follicular lymphoma
are associated with worse prognosis. Cancer Res. 70:9166–9174.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cancer Genome Atlas Research Network:
Comprehensive molecular characterization of urothelial bladder
carcinoma. Nature. 507:315–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: Limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Capesdavis A, Theodosopoulos G, Atkin I,
Drexler HG, Kohara A, MacLeod RA, Masters JR, Nakamura Y, Reid YA,
Reddel RR and Freshney RI: Check your cultures! A list of
cross-contaminated or misidentified cell lines. Int J Cancer.
127:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang D, Wang H, Wang J, Zhang C and Xu H:
Establishment of a fluorescent implantation metastasis model of
bladder cancer and real-time microscopic detection in nude mice.
Asian Pac J Cancer Prev. 12:393–396. 2011.PubMed/NCBI
|
|
15
|
Girnita A, All-Ericsson C, Economou MA,
Astrom K, Axelson M, Seregard S, Larsson O and Girnita L: The
insulin-like growth factor-I receptor inhibitor picropodophyllin
causes tumor regression and attenuates mechanisms involved in
invasion of uveal melanoma cells. Clin Cancer Res. 12:1383–1391.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang X, Qi H, Wang S, Feng L, Ji Y, Tao
L, Li S and Wei Y: Cellular responses of aniline oligomers: A
preliminary study. Toxicol Res. 1:201–205. 2012. View Article : Google Scholar
|
|
18
|
van Rhijn BW, Burger M, Lotan Y, Solsona
E, Stief CG, Sylvester RJ, Witjes JA and Zlotta AR: Recurrence and
progression of disease in non-muscle-invasive bladder cancer: From
epidemiology to treatment strategy. Eur Urol. 56:430–442. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Geng W, Ng KTP, Sun CKW, Yau WL, Liu XB,
Cheng Q, Poon RT, Lo CM, Man K and Fan ST: The role of proline rich
tyrosine kinase 2(Pyk2) on cisplatin resistance in hepatocellular
carcinoma. PLoS One. 6:e273622011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Harrop JA, Mcdonnell PC, Brigham-Burke M,
Lyn SD, Minton J, Tan KB, Dede K, Spampanato J, Silverman C,
Hensley P, et al: Herpesvirus entry mediator ligand (HVEM-L), a
novel ligand for HVEM/TR2, stimulates proliferation of T cells and
inhibits HT29 cell growth. J Biol Chem. 273:27548–27556. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gaur U and Aggarwal BB: Regulation of
proliferation, survival and apoptosis by members of the TNF
superfamily. Biochem Pharmacol. 66:1403–1408. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hengartner MO: Biochemistry of apoptosis.
Nature. 407:770–776. 2016. View
Article : Google Scholar
|
|
23
|
Hail N Jr, Carter BZ, Konopleva M and
Andreeff M: Apoptosis effector mechanisms: A requiem performed in
different keys. Apoptosis. 11:889–904. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hartmann A, Troadec J, Hunot S, Kikly K,
Faucheux B, Mouatt-Prigent A, Ruberg M, Agid Y and Hirsch E:
Caspase-8 is an effector in apoptotic death of dopaminergic neurons
in parkinson's disease, but pathway inhibition results in neuronal
necrosis. J Neurosci. 21:2247–2255. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Isabelle M, Moreel X, Gagné JP, Rouleau M,
Ethier C, Gagné P, Hendzel MJ and Poirier GG: Investigation of
PARP-1, PARP-2 and PARG interactomes by affinity-purification mass
spectrometry. Proteome Sci. 8:222010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shaw RJ and Cantley LC: Ras, PI(3)K and
mTOR signalling controls tumour cell growth. Nature. 441:424–430.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Knowles MA, Platt FM, Ross RL and Hurst
CD: Phosphatidylinositol 3-kinase (PI3K) pathway activation in
bladder cancer. Cancer Metastasis Rev. 28:305–316. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bakin AV, Tomlinson AK, Bhowmick NA, Moses
HL and Arteaga CL: Phosphatidylinositol 3-kinase function is
required for transforming growth factor β-mediated epithelial to
mesenchymal transition and cell migration. J Biol Chem.
275:368032000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mcconkey DJ, Choi W, Marquis L, Martin F,
Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, et al: Role
of epithelial-to-mesenchymal transition (EMT) in drug sensitivity
and metastasis in bladder cancer. Cancer Metastasis Rev.
28:335–344. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang YB, Qin J, Zheng XY, Bai Y, Yang K
and Xie LP: Diallyl trisulfide induces Bcl-2 and
caspase-3-dependent apoptosis via downregulation of Akt
phosphorylation in human T24 bladder cancer cells. Phytomedicine.
17:363–368. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tang C, Lu YH, Xie JH, Wang F, Zou JN,
Yang JS, Xing YY and Xi T: Downregulation of survivin and
activation of caspase-3 through the PI3K/Akt pathway in ursolic
acid-induced HepG2 cell apoptosis. Anticancer Drugs. 20:249–258.
2009. View Article : Google Scholar : PubMed/NCBI
|
